Q3 EPS Forecast for Rapt Therapeutics Lowered by Analyst

Rapt Therapeutics (NASDAQ:RAPT) – Equities research analysts at HC Wainwright reduced their Q3 2025 earnings estimates for shares of Rapt Therapeutics in a research note issued to investors on Monday, October 27th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($1.30) per share for the quarter, down from their previous forecast of ($1.15). HC Wainwright has a “Buy” rating and a $72.00 price objective on the stock. The consensus estimate for Rapt Therapeutics’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Rapt Therapeutics’ Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($1.30) EPS, FY2026 earnings at ($3.79) EPS, FY2027 earnings at ($5.87) EPS, FY2028 earnings at ($6.17) EPS and FY2029 earnings at ($7.06) EPS.

Other research analysts have also issued reports about the stock. UBS Group set a $9.00 target price on shares of Rapt Therapeutics and gave the stock a “neutral” rating in a research report on Tuesday, August 12th. Barclays upped their target price on shares of Rapt Therapeutics from $35.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 21st. Lifesci Capital upgraded shares of Rapt Therapeutics to a “strong-buy” rating and set a $31.00 target price for the company in a research report on Tuesday, July 22nd. Guggenheim started coverage on shares of Rapt Therapeutics in a research report on Monday. They issued a “buy” rating and a $70.00 target price for the company. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $48.00 target price (up previously from $38.00) on shares of Rapt Therapeutics in a report on Tuesday, October 21st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.20.

Rapt Therapeutics Stock Performance

Shares of NASDAQ:RAPT opened at $29.70 on Thursday. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $42.39. The firm has a fifty day moving average of $22.15 and a 200 day moving average of $13.37. The firm has a market capitalization of $491.24 million, a PE ratio of -2.10 and a beta of 0.23.

Rapt Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.04).

Institutional Investors Weigh In On Rapt Therapeutics

Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. grew its holdings in Rapt Therapeutics by 411.7% in the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after acquiring an additional 47,391 shares during the last quarter. Comerica Bank grew its holdings in Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company’s stock worth $109,000 after acquiring an additional 31,287 shares during the last quarter. Callan Family Office LLC grew its holdings in Rapt Therapeutics by 53.9% in the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company’s stock worth $109,000 after acquiring an additional 31,287 shares during the last quarter. Checkpoint Capital L.P. bought a new stake in Rapt Therapeutics in the 1st quarter worth $134,000. Finally, Nuveen LLC bought a new stake in Rapt Therapeutics in the 1st quarter worth $143,000. Institutional investors own 99.09% of the company’s stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.